Mutual of America Capital Management LLC Sells 1,372 Shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Mutual of America Capital Management LLC reduced its position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.5% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 92,357 shares of the company’s stock after selling 1,372 shares during the period. Mutual of America Capital Management LLC’s holdings in Amphastar Pharmaceuticals were worth $4,482,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in the business. GAMMA Investing LLC lifted its holdings in shares of Amphastar Pharmaceuticals by 70.0% in the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after purchasing an additional 273 shares in the last quarter. Innealta Capital LLC bought a new position in Amphastar Pharmaceuticals during the 2nd quarter valued at $55,000. Blue Trust Inc. grew its stake in shares of Amphastar Pharmaceuticals by 23.9% in the 2nd quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock worth $70,000 after acquiring an additional 309 shares in the last quarter. Asset Management One Co. Ltd. purchased a new stake in shares of Amphastar Pharmaceuticals in the third quarter valued at about $78,000. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Amphastar Pharmaceuticals by 20.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after purchasing an additional 301 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Price Performance

Amphastar Pharmaceuticals stock opened at $44.09 on Thursday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $65.92. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 0.89 and a beta of 0.82. The business has a 50-day simple moving average of $48.38 and a 200 day simple moving average of $44.42.

Insider Buying and Selling at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, EVP Rong Zhou sold 4,000 shares of the firm’s stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the completion of the transaction, the executive vice president now owns 118,388 shares in the company, valued at $5,724,059.80. This trade represents a 3.27 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Yakob Liawatidewi sold 5,214 shares of the stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $271,388.70. Following the transaction, the executive vice president now owns 74,938 shares of the company’s stock, valued at $3,900,522.90. This represents a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 31,533 shares of company stock worth $1,571,652 over the last three months. Company insiders own 27.10% of the company’s stock.

Analyst Ratings Changes

AMPH has been the subject of a number of recent analyst reports. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Finally, Piper Sandler dropped their price target on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.